Advertisement
Australia markets closed
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • AUD/USD

    0.6515
    -0.0020 (-0.31%)
     
  • OIL

    83.06
    +1.71 (+2.10%)
     
  • GOLD

    2,241.80
    +29.10 (+1.32%)
     
  • Bitcoin AUD

    108,525.73
    +2,848.36 (+2.70%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • AUD/EUR

    0.6039
    +0.0008 (+0.14%)
     
  • AUD/NZD

    1.0905
    +0.0025 (+0.23%)
     
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NASDAQ

    18,277.32
    -3.53 (-0.02%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • Dow Jones

    39,827.21
    +67.13 (+0.17%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     

MGC Pharmaceuticals' proprietary ZAM app "about good practice"

London, UK --News Direct-- MGC Pharmaceuticals Ltd

MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) chief commercial officer Robert Clements speaks to Proactive's Thomas Warner after announcing the enrolment of the first patient in its proprietary data collection App and machine learning algorithm, ZAM.

Clements explains why MGC is investing in medical technology, saying that "this is about good practice."

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/mgc-pharmaceuticals-proprietary-zam-app-about-good-practice-515065995